Evaluation of sex, race, body mass index and pre-vaccination serum progesterone levels and post-vaccination serum anti-anthrax protective immunoglobulin G on injection site adverse events following anthrax vaccine adsorbed (AVA) in the CDC AVA human clinical trial

Vaccine

Volumn 32, Issue 28, 2014, Pages 3548-3554

  Pondo, Tracy ^a   Rose, Charles E ^a   Martin, Stacey W ^a   Keitel, Wendy A ^c   Keyserling, Harry L ^d   Babcock, Janiine ^e   Parker, Scott ^f   Jacobson, Robert M ^g   Poland, Gregory A ^g   McNeil, Michael M ^b  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^g MAYO CLINIC   (United States)

Author keywords

Anthrax vaccine adsorbed; Anthrax vaccines adverse events; Body mass index; Immunological response; Race; Sex factors

Indexed keywords

ANTHRAX VACCINE; IMMUNOGLOBULIN G; PLACEBO; PROGESTERONE; BACTERIUM ANTIBODY;

ADULT; ANTIBODY RESPONSE; ARTICLE; BODY MASS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; INJECTION; INJECTION SITE; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MENSTRUAL CYCLE; MIDDLE AGED; MOTOR DYSFUNCTION; OBESITY; PAIN; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; PRURITUS; RACE; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SKIN BRUISING; SWELLING; VACCINATION; ANCESTRY GROUP; ANTHRAX; BLOOD; CLINICAL TRIAL; INTRAMUSCULAR DRUG ADMINISTRATION; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PHASE 4 CLINICAL TRIAL; STATISTICAL MODEL; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; ANTHRAX; ANTHRAX VACCINES; ANTIBODIES, BACTERIAL; BODY MASS INDEX; CONTINENTAL POPULATION GROUPS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOGLOBULIN G; INJECTIONS, INTRAMUSCULAR; INJECTIONS, SUBCUTANEOUS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGESTERONE; SEX FACTORS;

EID: 84901445864     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.04.025     Document Type: Article

References (44)

1. Bioport Corporation Anthrax Vaccine Adsorbed (BIOTHRAX™) Package Insert 2002, Bioport Corporation (Manufactured by), Lansing, MI, (US Lic. No. 1260).
2. Cohen W.A. Implementation of the Anthrax Vaccination Program for the Total Force 1998, The Secretary of Defense, 〈http://www.vaccines.mil/documents/902implementationpolicy.pdf〉 (accessed June 12, 2013).
3. Sever J.L., Brenner A.I., Gale A.D., Lyle J.M., Moulton L.H., Ward B.J., et al. Safety of anthrax vaccine: an expanded review and evaluation of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS). Pharmacoepidemiol Drug Saf 2004, 13(12):825-840.
4. Lange J.L., Lesikar S.E., Rubertone M.V., Brundage J.F. Comprehensive systematic surveillance for adverse events of anthrax vaccine adsorbed, US Armed Forces 1998-2000. Vaccine 2003, 21(15):1620-1628.
5. Committee to Assess the Safety and Efficacy of the Anthrax Vaccine, Medical Follow-up Agency The anthrax vaccine. Is it safe? Does it work? 2002, Institute of Medicine, National Academy Press, Washington, DC.
6. Pittman P.R., Gibbs P.H., Cannon T.L., Friedlander A.M. Anthrax vaccine: short-term safety experience in humans. Vaccine 2001, 20(5-6):972-978.
7. Pittman P.R., Kim-Ahn G., Pifat D.Y., Coonan K., Gibbs P., Little S., et al. Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans. Vaccine 2002, 20(9-10):1412-1420.
8. Hoffman K., Costello C., Menich M., Grabenstein J.D., Engler R.J. Using a structured medical note for determining the safety profile of anthrax vaccine for US soldiers in Korea. Vaccine 2003, 21(27):4399-4409.
9. Ryan M.A., Smith T.C., Sevick C.J., Honner W.K., Loach R.A., Moore C.A., et al. Birth defects among infants born to women who received anthrax vaccine in pregnancy. Am J Epidemiol 2008, 168(4):434-442.
10. Weisen A.R., Littell C.T. Relationship between prepregnancy anthrax vaccination and pregnancy and birth outcomes among US Army women. JAMA 2002, 287(12):1556-1560.
11. Catherino W.H., Levi A.K., Kao T.C., Leondires M.P., McKeeby J., Segars J.H. Anthrax vaccine does not affect semen parameters, embryo quality, or pregnancy outcome in couples with a vaccinated male military service member. Fertil Steril 2005, 83(2):480-483.
12. Sulsky S.I., Grabenstein J.D., Delbos R.G. Disability among US Army personnel vaccinated against anthrax. J Occup Environ Med 2004, 46(10):1065-1075.
13. Sulsky S.I., Luippold R.S., Garman P., Hughes H., Amoroso P.J. Risk of disability for US army personnel vaccinated against anthrax, 1998-2005. Vaccine 2011, 29(35):6035-6041.
14. Sulsky S.I., Luippold R., Garman P., Hughes H., Boyko E.J., Maynard C., et al. Disability among US Army veterans vaccinated against anthrax. Vaccine 2012, 30(43):6150-6156.
15. Downing J., Greig T.W., Quattlebaum M.D., Valentin M., Heeren T.C., Grabenstein J.D. Assessing the safety of anthrax immunization in US Army aircrew members via physical examination. J Occup Environ Med 2007, 49(10):1079-1085.
16. Shoenfeld Y., Agmon-Levin N. 'ASIA'-autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmun 2011, 36(1):4-8.
17. Rook G., Zumla A. Gulf War syndrome: is it due to a systemic shift in cytokine balance towards a Th2 profile?. Lancet 1997, 349(9068):1831-1833.
18. Nicolson G.L., Marwan Y.N., Nicolson N.L., Haier J. High prevalence of mycoplasmal infection in symptomatic (chronic fatigue syndrome) family members of mycoplasma-positive Gulf War Illness patients. J Chronic Fatigue Syndr 2003, 11(2):21-36.
19. Appel S., Chapman J., Shoenfeld Y. Infection and vaccination in chronic fatigue syndrome: myth or reality?. Autoimmunity 2007, 40(1):48-53.
20. Committee to Assess the Safety and Efficacy of the Anthrax Vaccine, Medical Follow-up Agency An Assessment of the CDC Anthrax Vaccine Safety and Efficacy Research Program 2002, Institute of Medicine, National Academy Press, Washington, DC.
21. Sun W. Biologics license application supplement approval letter 2008, Food and Drug Administration, 〈http://www.fda.gov/biologicsbloodvaccines/vaccines/approvedproducts/ucm124462.htm〉 (accessed June 12, 2013).
22. CDC. Advisory Committee on Immunization Practices (ACIP) meeting minutes archive. n.d. .(accessed June 12, 2013).
23. CDC Use of Anthrax Vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) 2009. MMWR Recomm Rep 2010, 59:1-30.
24. Marano N., Plikaytis B.D., Martin S.W., Rose C., Semenova V.A., Martin S.K., et al. Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months. JAMA 2008, 300(13):1532-1543.
25. Wright J.G., Plikaytis B.D., Rose C.E., Parker S.D., Babcock J., Keitel W., et al. Effect of reduced dose schedules and intramuscular injection of anthrax vaccine adsorbed on immunological response and safety profile: a randomized trial. Vaccine 2014, 32(8):1019-1028.
26. CDC. About BMI for Adults, Centers for Disease Control and Prevention. n.d. 〈http://www.cdc.gov/healthyweight/assessing/bmi/adult_bmi/index.html〉 (accessed January 25, 2013).
27. Quinn C.P., Semenova V.A., Elie C.M., Romero-Steiner S., Greene C., Li H., et al. Specific, sensitive, and quantitative enzyme-linked immunosorbent assay for human immunoglobulin G antibodies to anthrax toxin protective antigen. Emerg Infect Dis 2002, 8(10):1103-1110.
28. ADVIA Centaur, ReadyPack and ACS 180 1998, Siemens Medical Solutions USA, Inc., Malvern, PA.
29. Localio R.A., Margolis D.J., Berlin J.A. Relative risks and confidence intervals were easily computed indirectly from multivariable logistic regression. J Clin Epidemiol 2007, 60(9):874-882.
30. Zhang Y., Martin S.W., Rose C.E., Biagini R.E., Franzke L.H., Smith J.P., et al. Evaluation of body mass index, pre-vaccination serum progesterone levels and anti-anthrax protective antigen immunoglobulin G on injection site adverse events following anthrax vaccination in women. Pharmacoepidemiol Drug Saf 2008, 17(11):1060-1067.
31. Monath T.P., Nichols R., Archambault W.T., Moore L., Marchesani R., Tian J., et al. Comparative safety and immunogenicity of two yellow fever 17d vaccines (Arilvax and YF-Vax) in a phase 3 multicenter, double-blind clinical trial. Am J Trop Med Hyg 2002, 66(5):533-541.
32. Christy C., Pichichero M.E., Reed G.F., Decker M.D., Anderson E.L., Rennels M.B., et al. Effect of gender, race, and parental education on immunogenicity and reported reactogenicity of acellular and whole-cell pertussis vaccines. Pediatrics 1995, 96(3):584-587.
33. Cook I.F. Sexual dimorphism of humoral immunity with human vaccines. Vaccine 2008, 26(29):3551-3555.
34. Cook I.F. Sex differences in injection site reactions with human vaccines. Hum Vaccin 2009, 5(7):441-449.
35. Klein S.L., Jedlicka A., Pekosz A. The Xs and Y of immune responses to viral vaccines. Lancet Infect Dis 2010, 10(5):338-349.
36. Engler R.J., Nelson M.R., Klote M.M., VanRaden M.J., Huang C.Y., Cox N.J., et al. Half-vs full-dose trivalent inactivated influenza vaccine (2004-2005): age, dose, and sex effects on immune responses. Arch Intern Med 2008, 168(22):2405-2414.
37. Nichol K.L., Margolis K.L., Lind A., Murdoch M., McFadden R., Hauge M., et al. Side effects associated with influenza vaccination in healthy working adults: a randomized, placebo-controlled trial. Arch Intern Med 1996, 156(14):1546-1550.
38. Khalil M.K., Al-Mazrou Y.Y., Al-Ghamdi Y.S., Tumsah S., Al-Jeffri M., Meshkhas A. Effect of gender on reporting of MMR adverse events in Saudi Arabia. East Mediterr Health J 2003, 9(1-2):152-158.
39. Benjamin C.M., Chew G.C., Silman A.J. Joint and limb symptoms in children after immunisation with measles, mumps, and rubella vaccine. BMJ 1992, 304(6834):1075-1078.
40. Pennell L.M., Galligan C.L., Fish E.N. Sex affects immunity. J Autoimmun 2012, 38(2):J282-J291.
41. Verthelyi D. Sex hormones as immunomodulators in health and disease. Int Immunopharmacol 2001, 1(6):983-993.
42. Ahmed S.A., Hissong B.D., Verthelyi D., Donner K., Becker K., Karpuzoglu-Sahin E. Gender and risk of autoimmune disease: possible role of estrogenic compounds. Environ Health Perspect 1999, 107(Suppl 5):681-686.
43. Lahita R.G. Sex hormones and the immune system-Part 1. Human data. Baillière's Clin Rheumatol 1990, 4(1):1-12.
44. ® analyzer. Clin Chem Lab Med 2006, 44(7):883-887.